rdf:type |
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0069717,
umls-concept:C0205179,
umls-concept:C0205267,
umls-concept:C0205390,
umls-concept:C0524669,
umls-concept:C0549178,
umls-concept:C0596581,
umls-concept:C1274040,
umls-concept:C1521750,
umls-concept:C1527249,
umls-concept:C1540289,
umls-concept:C1708063,
umls-concept:C2698590
|
pubmed:issue |
7
|
pubmed:dateCreated |
2011-6-28
|
pubmed:databankReference |
|
pubmed:abstractText |
When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation of time without toxic effects could be one effective strategy to achieve both of these goals. The COIN trial assessed preplanned treatment holidays in advanced colorectal cancer to achieve this aim.
|
pubmed:grant |
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-11886010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-12583944,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-15169984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-15987918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-16421419,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-16921042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-17045796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-17630037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-17664470,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-19105712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-19109157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-19786657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-21183212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-21709694,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21641867-8932983
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1474-5488
|
pubmed:author |
pubmed-author:AdamsRichard ARA,
pubmed-author:BessellEric MEM,
pubmed-author:FalkStephenS,
pubmed-author:FisherDavidD,
pubmed-author:GollinsSimonS,
pubmed-author:HickishTamasT,
pubmed-author:HodgkinsonElizabethE,
pubmed-author:KaplanRichardR,
pubmed-author:KayEdwardE,
pubmed-author:KennedyM JohnMJ,
pubmed-author:KennySarah LSL,
pubmed-author:MRC COIN Trial Investigators,
pubmed-author:MadiAymanA,
pubmed-author:MaughanTimothy STS,
pubmed-author:MeadeAngela MAM,
pubmed-author:PopeMalcolmM,
pubmed-author:PropperDavidD,
pubmed-author:RogersPennyP,
pubmed-author:SeymourMatthew TMT,
pubmed-author:WasanHarpreetH,
pubmed-author:WilsonRichard HRH
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
642-53
|
pubmed:dateRevised |
2011-9-14
|
pubmed:meshHeading |
pubmed-meshheading:21641867-Aged,
pubmed-meshheading:21641867-Antimetabolites, Antineoplastic,
pubmed-meshheading:21641867-Antineoplastic Agents,
pubmed-meshheading:21641867-Colorectal Neoplasms,
pubmed-meshheading:21641867-Disease Progression,
pubmed-meshheading:21641867-Disease-Free Survival,
pubmed-meshheading:21641867-Drug Therapy, Combination,
pubmed-meshheading:21641867-Female,
pubmed-meshheading:21641867-Fluorouracil,
pubmed-meshheading:21641867-Follow-Up Studies,
pubmed-meshheading:21641867-Humans,
pubmed-meshheading:21641867-Male,
pubmed-meshheading:21641867-Middle Aged,
pubmed-meshheading:21641867-Neoplasm Staging,
pubmed-meshheading:21641867-Organoplatinum Compounds,
pubmed-meshheading:21641867-Quality of Life,
pubmed-meshheading:21641867-Time Factors
|
pubmed:year |
2011
|
pubmed:articleTitle |
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
|
pubmed:affiliation |
School of Medicine, Cardiff University, Cardiff, UK.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|